In vitro metabolism of the lignan (−)‐grandisin, an anticancer drug candidate, by human liver microsomes

E-ISSN： 1942-7611|7|9|780-786

ISSN： 1942-7603

Source： DRUG TESTING AND ANALYSIS, Vol.7, Iss.9, 2015-09, pp. : 780-786

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

(−)‐grandisin is a tetrahydrofuran lignan that displays important biological properties, such as trypanocidal, anti‐inflammatory, cytotoxic, and antitumor activities, suggesting its utility as a potential drug candidate. One important step in drug development is metabolic characterization and metabolite identification. To perform a biotransformation study of (−)‐grandisin and to determine its kinetic properties in humans, a high performance liquid chromatography (HPLC) method was developed and validated. After HPLC method validation, the kinetic properties of (−)‐grandisin were determined. (−)‐grandisin metabolism obeyed Michaelis‐Menten kinetics. The maximal reaction rate (Vmax) was 3.96 ± 0.18 µmol/mg protein/h, and the Michaelis‐Menten constant (Km) was 8.23 ± 0.99 μM. In addition, the structures of the metabolites derived from (−)‐grandisin were characterized via gas chromatography‐mass spectrometry (GC‐MS) and liquid chromatography‐mass spectrometry (LC‐MS) analysis. Four metabolites, 4‐O‐demethylgrandisin, 3‐O‐demethylgrandisin, 4,4′‐di‐O‐demethylgrandisin, and a metabolite that may correspond to either 3,4‐di‐O‐demethylgrandisin or 3,5‐di‐O‐demethylgrandisin, were detected. CYP2C9 isoform was the main responsible for the formation of the metabolites. These metabolites have not been previously described, demonstrating the necessity of assessing (−)‐grandisin metabolism using human‐derived materials. Copyright © 2015 John Wiley & Sons, Ltd.